Contribution of Type II PLA2 to prostaglandin formation: A study using a Type II PLA2 specific inhibitor SB 203347

Prostaglandins and Other Lipid Mediators

Volumn 57, Issue 5-6, 1999, Pages 361-370

  Munns, M J ^a   King, R G ^b   Rice, G E ^a,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CHO cells; Phospholipase A2; Placenta; Prostaglandin F(2 ); SB 203347

Indexed keywords

ISOENZYME; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; SB 203347; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVITY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PLACENTA; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS;

ANIMALS; CHO CELLS; CRICETINAE; DINOPROST; ENZYME INHIBITORS; HUMANS; ISOENZYMES; PHOSPHOLIPASES A; PLACENTA; RADIOIMMUNOASSAY; SUBSTRATE SPECIFICITY; SULFONAMIDES; TRANSFECTION;

EID: 0032842544     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(99)00012-X     Document Type: Article

References (18)

1. Rice G.E. Glycerophospholipid metabolism and human labour. Reprod Fertil Dev. 7:1995;613-622.
2. 2 in the pathobiology of disease. Lab Invest. 55:1986;391-404.
3. 2 has anticoagulant activity in vitro on human plasma. Thrombosis Res. 70:1993;337-342.
4. 2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation. 15:1991;355-367.
5. 2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin some implications for its functional role . Biochem J. 306:1995;167-175.
6. 2 enzyme activity from human placenta. J Endocrinol. 153:1997;151-157.
7. 2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J Pharmacol Exp Ther. 274:1995;1254-1262.
8. 2 by synthetic peptides derived from the primary sequences. J Biol Chem. 271:1996;23992-23998.
9. Gebert C.A., Gray P.P. Expression of FSH in CHO cells. I. Comparison of promoter types and effects of their respective inducers. Cytotechnology. 14:1994;39-45.
10. 2 in human gestational tissues - subcellular distribution of placental immunoactivity and catalytic activity. Biochim Biophys Acta. 1166:1993;77-83.
11. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
12. Bartlett M.S., Kendall D.G. The statistical analysis of variance - heterogeneity and the logarithmic transformation. J Roy Statist Soc Suppl. 8:1946;128-138.
13. 2 enzymatic activity in human term placenta. J Endocrinol. 157:1998;25-31.
14. 2α release by microtubule depolymerising agents. Clin Exp Pharmacol Physiol. 26:1999;230-235.
15. 2 does not alter leukotriene formation. J Biol Chem. 272:1997;759-784.
16. 4 release . J Pharmacol Exp Ther. 284:1998;847-857.
17. Duchesne M.J., Thaler-Dao H., de-Paulet A.C. Prostaglandin synthesis in human placenta and fetal membranes. Prostaglandins. 15:1978;19-42.
18. North R.A., Whitehead R., Larkins R.G. Stimulation by human chorionic gonadotropin of prostaglandin synthesis by early human placental tissue. J Clin Endocrinol Metab. 73:1991;60-70.